Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urine Test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,385 result(s) found for: Urine Test. Displaying page 46 of 320.
    «« First « Previous 42  43  44  45  46  47  48  49  50  Next» Last»»
    EudraCT Number: 2007-000710-37 Sponsor Protocol Number: ZLB06_006CR Start Date*: 2007-12-10
    Sponsor Name:CSL Behring AG
    Full Title: A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN)
    Medical condition: Patients with multifocal motor neuropathy, who are treated successful with IVIG and had a stable IVIG treatment schedule for at least 12 weeks prior to screening.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065579 Multifocal motor neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003929-83 Sponsor Protocol Number: ML 20469/GOIRC Start Date*: 2006-11-23
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
    Medical condition: Patients with advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002369-37 Sponsor Protocol Number: GID23 Start Date*: 2006-09-25
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Lot-to-Lot Consistency Study of the Investigational, Split-virion, Inactivated Influenza Vaccine, Administered by the Intradermal Route in Adults.
    Medical condition: Vaccination of adults aged 18 to 60 years with inactivated, split-virion influenza vaccine administered by the intradermal route using Vaxigrip® as IM reference vaccine.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004686-18 Sponsor Protocol Number: 539 Start Date*: 2008-02-08
    Sponsor Name:Bausch&Lomb Dr Gerhard Mann chem.-Fabrik GmbH
    Full Title: A multicenter, Investigator-Masked, Parallel Group, Randomized, Study of the Efficacy and Safety of Indomethacin 0.1% Eyedrops Compared with Ketorolac 0.5% Eyedrops in the Ocular Inflammation After...
    Medical condition: Prevention of ocular inflammation in adults patients undergoing cataract surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004000-33 Sponsor Protocol Number: INZ701-201 Start Date*: 2021-06-10
    Sponsor Name:Inozyme Pharma, Inc.
    Full Title: A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period i...
    Medical condition: Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003370-15 Sponsor Protocol Number: TPU-TT-EU05-01 Start Date*: 2005-11-03
    Sponsor Name:Teikoku Pharma USA, Inc.
    Full Title: Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Teikoku Tulobuterol Tape in Adults with Bronchial Asthma
    Medical condition: Bronchial Asthma (persistent)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-000685-12 Sponsor Protocol Number: MC2-01-C6 Start Date*: Information not available in EudraCT
    Sponsor Name:MC2 Therapeutics Ltd
    Full Title: A Multicentre, Open-label, Single-group Maximal Use Trial, Evaluating the Safety and Pharmacokinetic Profile of the Active Ingredients and their Metabolites after application of MC2-01 Cream in Ado...
    Medical condition: Extensive Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000348-77 Sponsor Protocol Number: XL184-315 Start Date*: 2020-07-22
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant ...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) PT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) AT (Completed) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015507-52 Sponsor Protocol Number: CLBH589D2308 Start Date*: 2009-11-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma
    Medical condition: Multiple Myeloma (MM), relapsed or relapsed-and-refractory
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) IT (Completed) FR (Completed) ES (Completed) CZ (Completed) PL (Completed) GB (Completed) AT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001205-16 Sponsor Protocol Number: 54767414SMM3001 Start Date*: 2017-10-18
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
    Medical condition: Smoldering multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004138-12 Sponsor Protocol Number: 6294-CL-0101 Start Date*: 2017-09-26
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment o...
    Medical condition: Bladder Pain Syndrome/Interstitial Cystitis (BPC/IC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10071166 Bladder pain syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed) BE (Completed) PL (Completed) NL (Completed) LV (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004079-11 Sponsor Protocol Number: D5495C00002 Start Date*: 2019-06-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricaemia
    Medical condition: Chronic kidney disease and hyperuricaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) ES (Ongoing) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-006118-19 Sponsor Protocol Number: 2020-012-00EU1 Start Date*: 2021-05-04
    Sponsor Name:Hutchison MediPharma Limited
    Full Title: An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe
    Medical condition: Neuroendocrine Tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NO (Completed) IT (Completed) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2018-002147-28 Sponsor Protocol Number: CT-P16_3.1 Start Date*: 2018-12-10
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non...
    Medical condition: Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001010-14 Sponsor Protocol Number: XL184-308 Start Date*: 2013-08-15
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) SE (Completed) BE (Completed) CZ (Completed) PT (Completed) IE (Completed) IT (Completed) NL (Completed) SK (Completed) GB (Completed) ES (Completed) DE (Completed) DK (Completed) FR (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002416-27 Sponsor Protocol Number: INFECIR2 Start Date*: 2013-10-23
    Sponsor Name:Fundacio Clinic per a la recerca biomedica
    Full Title: Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital mo...
    Medical condition: Patients with advanced cirrhosis (serum creatinine > 1.2 mg/dl, serum sodium < 130 mEq/l and/or serum bilirubin > 4 mg/dl), signs of systemic inflammation and urinary infection, pneumonia, skin/sof...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    16.0 10019805 - Hepatobiliary disorders 10008954 Chronic liver disease and cirrhosis LLT
    16.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    16.0 10019805 - Hepatobiliary disorders 10064704 Decompensated cirrhosis LLT
    16.0 10019805 - Hepatobiliary disorders 10009213 Cirrhosis of liver LLT
    16.0 10019805 - Hepatobiliary disorders 10009211 Cirrhosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) ES (Ongoing) IT (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000697-20 Sponsor Protocol Number: GE-GRANOANTICO-2008 Start Date*: 2008-04-15
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: PHASE II TRIAL TO EVALUATE EFFICACY AND SECURITY OF ACUTE INTAKE OF GLUTEN DERIVED FROM TRITICUM MONOCOCCUM IN PATIENTS AFFECTED BY CELIAC DISEASE: THE "ANCIENT WHEAT" PROJECT
    Medical condition: Celiac disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007865 Celiac sprue LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002871-36 Sponsor Protocol Number: VIR-7831-5001 Start Date*: 2020-11-27
    Sponsor Name:Vir Biotechnology, Inc.
    Full Title: A randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) i...
    Medical condition: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004031-37 Sponsor Protocol Number: 17.14 Start Date*: 2017-12-07
    Sponsor Name:Department of oncology, Odense University Hospital
    Full Title: A multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo® (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients rece...
    Medical condition: Eligible patients will have a diagnosis of cervical cancer, and be scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks. P...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000128-16 Sponsor Protocol Number: 2011-003 Start Date*: 2012-07-30
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 42  43  44  45  46  47  48  49  50  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:03:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA